摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

bryostatin 1 | 343601-44-5

中文名称
——
中文别名
——
英文名称
bryostatin 1
英文别名
[(1R,3S,7S,8E,11S,12S,13E,15S,17R,21R,23S)-11,21-dihydroxy-17-(hydroxymethyl)-13-(2-methoxy-2-oxoethylidene)-10,10-dimethyl-19-oxo-6,18,27,28,29-pentaoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl] octanoate
bryostatin 1化学式
CAS
343601-44-5
化学式
C38H60O13
mdl
——
分子量
724.887
InChiKey
NFEHLOAACAEFIK-UZJFSINNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    51
  • 可旋转键数:
    11
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    177
  • 氢给体数:
    3
  • 氢受体数:
    13

反应信息

  • 作为反应物:
    描述:
    bryostatin 1二甲基二环氧乙烷 作用下, 以 丙酮 为溶剂, 反应 48.0h, 以70%的产率得到
    参考文献:
    名称:
    Late-Stage Intermolecular CH Activation for Lead Diversification:  A Highly Chemoselective Oxyfunctionalization of the C-9 Position of Potent Bryostatin Analogues
    摘要:
    Treatment of highly potent and densely functionalized bryostatin analogue 1 with dimethyldioxirane afforded the C-9 hydroxylated hemiketal 2 via oxylunctionalization of the C9-CH bond, one of 12 CH bonds geminal to an oxygen substituent in 1. When bryostatin analogue 3 was subjected to identical conditions, oxidation of a C-26 secondary hydroxyl group was found to compete with C-9 hydroxylation. Complete selectivity for C-9 hydroxylation was restored upon acylation of the C-26 secondary alcohol.
    DOI:
    10.1021/ol047859w
  • 作为产物:
    描述:
    3-(tert-butyldiphenylsilanyloxy)-4-[6-(2,2-dimethyl-[1,3]dioxan-4-ylmethyl)-tetrahydropyran-2-yl]-butan-1-ol 在 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochloritesodium chlorite氢氟酸N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下, 以 四氢呋喃吡啶 、 phosphate buffer 、 二氯甲烷乙腈 为溶剂, 反应 23.0h, 生成 bryostatin 1
    参考文献:
    名称:
    A Concise, Selective Synthesis of the Polyketide Spacer Domain of a Potent Bryostatin Analogue
    摘要:
    [GRAPHICS]A concise, asymmetric synthesis of the polyketide spacer domain portion (C1-C13) of a highly potent bryostatin analogue was developed. The route utilizes asymmetric hydrogenation methodology to install the C3, C5, and C11 stereocenters, while a substrate directed syn reduction sets the C9 stereocenter. The spacer domain 1 is obtained in 10 steps with a 25% overall yield and is readily incorporated into the synthesis of 2.
    DOI:
    10.1021/ol0272390
点击查看最新优质反应信息

文献信息

  • BRYOSTATIN ANALOGUES, SYNTHETIC METHODS AND USES
    申请人:WENDER PAUL A.
    公开号:US20090270492A1
    公开(公告)日:2009-10-29
    Biologically active compounds related to the bryostatin family of compounds, including methods of utilizing the same.
    与拟静脉注射家族相关的生物活性化合物,包括利用这些化合物的方法。
  • PROSTRATIN ANALOGS, BRYOSTATIN ANALOGS, PRODRUGS, SYNTHETIC METHODS, AND METHODS OF USE
    申请人:Wender Paul A.
    公开号:US20110014699A1
    公开(公告)日:2011-01-20
    Embodiments of the present disclosure provide for prostratin analogs, bryostatin analogs, prodrugs of prostratin and prostratin analogs, methods of making prostratin analogs, and methods of making prodrugs of prostratin and prostratin analogs, methods of use of prostratin analogs, bryostatin analogs, and prodrugs thereof, and the like.
    本公开的实施例提供了prostratin类似物、bryostatin类似物、prostratin和prostratin类似物的前药、制备prostratin类似物的方法,以及制备prostratin和prostratin类似物的前药的方法,使用prostratin类似物、bryostatin类似物及其前药的方法等。
  • PKC ACTIVATORS AND COMBINATIONS THEREOF
    申请人:BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE
    公开号:US20140315990A1
    公开(公告)日:2014-10-23
    The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.
    本公开涉及PKC激活剂及其组合物。本公开进一步涉及其组成物、套件、用途和方法。
  • Treatment of depressive disorders
    申请人:Blanchette Rockefeller Neuroscience Institute
    公开号:US10010584B2
    公开(公告)日:2018-07-03
    The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds to treat depressive disorders.
    本发明提供了使用碳酸酐酶激活剂、蛋白激酶 C 激活剂和 FGF-18 治疗抑郁障碍的方法。本发明还涉及用于筛选和鉴定治疗抑郁障碍的化合物的改良动物模型和方法。
  • Byrostatin analogues, synthetic methods and uses
    申请人:Wender A. Paul
    公开号:US20070270485A1
    公开(公告)日:2007-11-22
    Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same.
查看更多